The effect of delayed graft function on graft and patient survival in kidney transplantation: an approach using competing events analysis by Fonseca, I et al.
ORIGINAL ARTICLE
The effect of delayed graft function on graft and patient
survival in kidney transplantation: an approach using
competing events analysis
Isabel Fonseca,1,2,3 Laetitia Teixeira,4,3 Jorge Malheiro,1,2 La Salete Martins,1,2 Leonıdio Dias,1
Antonio Castro Henriques1,2 and Denisa Mendonca4,3
1 Department of Nephrology and Kidney Transplantation, Centro Hospitalar do Porto, Hospital de Santo Antonio, Porto, Portugal
2 Unit for Multidisciplinary Investigation in Biomedicine (UMIB), Porto, Portugal
3 EPIUnit-Institute of Public Health, University of Porto, Porto, Portugal
4 Department of Population Studies, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal
Keywords
kidney transplantation, delayed graft function,
competing risks analysis, long-term graft
failure, patient death with graft function,
subdistribution hazard regression model.
Correspondence
Isabel Fonseca, Department of Nephrology
and Kidney Transplantation, Centro Hospitalar
do Porto, Hospital de Santo Antonio,
Largo Prof. Abel Salazar, 4099-001 Porto,
Portugal.
Tel.: +351914740001;
fax: 223 320 318
e-mail: isabelf27@gmail.com
Competing interests
The authors declare that they have no
competing interests. The results presented in
this study have not been published previously
in whole or part, neither in abstract format.
Received: 19 October 2014
Revision requested: 30 November 2014
Accepted: 6 February 2015
Published online: 26 February 2015
doi:10.1111/tri.12543
Abstract
Objective: In kidney transplantation, the impact of delayed graft function (DGF)
on long-term graft and patient survival is controversial. We examined the impact
of DGF on graft and recipient survival by accounting for the possibility that death
with graft function may act as a competing risk for allograft failure.
Study design and Setting: We used data from 1281 adult primary deceased-
donor kidney recipients whose allografts functioned at least 1 year.
Results: The probability of graft loss occurrence is overestimated using the com-
plement of Kaplan–Meier estimates (1-KM). Both the cause-specific Cox propor-
tional hazard regression model (standard Cox) and the subdistribution hazard
regression model proposed by Fine and Gray showed that DGF was associated
with shorter time to graft failure (csHR = 2.0, P = 0.002; sHR = 1.57,
P = 0.009), independent of acute rejection (AR) and after adjusting for tradi-
tional factors associated with graft failure. Regarding patient survival, DGF was a
predictor of patient death using the cause-specific Cox model (csHR = 1.57,
P = 0.029) but not using the subdistribution model.
Conclusions: The probability of graft loss from competing end points should
not be reported with the 1-KM. Application of a regression model for subdistri-
bution hazard showed that, independent of AR, DGF has a detrimental effect on
long-term graft survival, but not on patient survival.
Introduction
Delayed graft function (DGF) is the most common com-
plication affecting kidney allografts in the immediate
post-transplant period. The rate of DGF after kidney
transplantation (KTx) can vary from 2% to 50% depend-
ing on the definition and the practice center, and it is one
of the most important risk factors for both acute rejection
(AR) and impaired renal function at one year [1–4].
The impact of DGF on long-term graft survival is con-
troversial [4]. Some single-center studies have reported
limited or no impact of DGF on long-term graft survival in
the absence of AR [5–8] while others have associated DGF
with poor graft outcome independent of rejection [9–12].
Some authors have examined the association between DGF
and patient survival, also with conflicting findings. Some of
those studies reported no association between DGF with
patient death with a functioning graft [6, 13], whereas
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others showed a negative effect of DGF on survival of KTx
recipients [9, 14–17].
Survival analysis is used to analyze time-to-event data
and is commonly used in medical research [18]. In KTx,
the Kaplan–Meier curves are one of the most used method-
ologies to study graft and patient survival, which censor all
but one type of outcome. However, a patient can be at risk
for more than one type of events and experience an event
different from the outcome of interest. For example, when
analyzing kidney allograft survival, the event of interest is
chronic graft loss, but other events can be observed, namely
patient death with graft function. These two events are
termed competing risk events. That is, a competing risk is
an event whose occurrence either precludes the occurrence
of another event under examination or fundamentally
alters the probability of occurrence of this other event [19,
20]. If a recipient dies, the decline and loss of graft function
cannot be observed. Graft failure and patient death are
competing end points that are mutually exclusive. Thus,
appropriate methods accounting for the presence of com-
peting risk events must be applied in the analysis and inter-
pretation of such data.
Inappropriate methods such as the complement of Kap-
lan–Meier estimate (1-KM) have been applied to estimate
probabilities of the occurrence of an event of interest in a
competing risks setting [21] [19, 21–23]. This method pro-
duces biased estimates of end point probabilities because
does not account for the various types of potential out-
comes [20, 24]. In other words, the probability of an event
of interest (e.g., graft failure) is estimated in an ideal world
in which the other types of events do not exist (patient
death, for example). Thus, when competing risks are pres-
ent, cumulative incidence function (CIF) is the appropriate
tool to analyse such data [22, 25]. Cumulative incidence
function for a specific event, also known as the subdistribu-
tion function, is defined as the probability of failing from a
given cause in the presence of competing events, given that
a subject has survived or has already failed from different
causes [20, 26, 27]. In other words, the cumulative inci-
dence denotes the expected proportion of patients with a
certain event over the course of time [22].
In the competing risks context and depending on the
purpose of the study, there are different methods to quan-
tify the effect of a covariate [22, 23]. The most common
methods are the regression on cause-specific hazards using
the competing risks analog to the Cox proportional hazards
model, and the regression model for the cumulative inci-
dence function proposed by Fine and Gray [26]. This
method is based on the hazard of the subdistribution, pro-
viding a simple relationship between covariates and CIF,
and is recommended for a competing risk approach [20,
26, 28]. As in any other regression analysis, modeling CIF
can be used to identify potential prognostic factors for a
particular failure in the presence of competing risks or to
assess a prognostic factor of interest after adjusting for
other potential risk factors in the model [27].
The kidney transplant program at our center began in
1983. From that time to the present, the rates of DGF var-
ied due to the distinctive immunosuppressive protocols
introduced, the inclusion of kidneys from living donors,
and more recently the inclusion of expanded-criteria
donors (ECD). We reviewed our KTx experience over the
past three decades to study what effect evolving DGF (with
and without AR associated) had on patient and long-term
kidney transplant outcomes. Our analysis further supple-
ments the current state of knowledge by assessing the
impact of DGF on graft and recipient survival and by
accounting for the possibility that death with graft function
may act as a competing risk for allograft failure.
Materials and methods
Subjects and study design
This retrospective single-center study used data from the
renal transplant database of the Department of Nephrology
and Kidney Transplantation of Centro Hospitalar do Porto.
Analyses were conducted on data from adult recipients
who received a primary deceased-donor kidney transplant
from August 1983 through December 2012 at this center
and had a functioning renal allograft for at least 1 year.
Exclusion criteria were (i) patients younger than 18 years
old (n = 144), (ii) multi-organ transplant recipients,
including kidney–pancreas (n = 169), (iii) retransplants
(n = 163), (iv) recipients of living kidney donor (n = 150),
and (v) recipients whose allografts functioned <1 year
(n = 196). Patients with missing data on DGF or AR were
also excluded from the analysis (n = 33, 2.5% of the final
cohort). Because organ donation after circulatory death is
not performed in our country, all donations occurred after
brain death.
All patients were followed up from the time of transplant
until death, graft failure or until December 31, 2013. The
study was approved for the Institutional Review Board of
Centro Hospitalar do Porto.
Definitions, variable categorization and main outcomes
The primary exposure of interest was the development of
DGF after transplantation, with or without AR. In the cur-
rent study, DGF was defined as the need for dialysis during
the first week after transplantation. This definition was the
same over the observation period of the three decades.
Acute rejection was defined as either biopsy-proven rejec-
tion or antirejection treatment without biopsy. A variable
“DGF-AR” was created with four categories: neither DGF
nor AR; only DGF; only AR; DGF and AR. The cause of
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kidney disease was categorized into three groups represent-
ing glomerular disease, diabetes, and all other diseases.
The study sample was divided into four cohorts based on
the times in which immunosuppressive medications were
introduced into clinical practice (“Transplant Era”): “Era” 1,
before 1990, the time of azathioprine and cyclosporine, no mi-
croemulsion; “Era” 2, between 1990 and 1995, the era of
cyclosporine microemulsion; “Era” 3, between 1996 and 2000,
marked by mycophenolate mofetil introduction and by the
wide use of antithymocyte globulin; and “Era” 4, after 2000,
the time of sirolimus availability and wide use of tacrolimus.
Time on dialysis prior to transplant was categorized as <
and ≥5 years. Peak panel reactive antibody level (PRA-
peak) was categorized into two categories according to the
cutoff of 10%.
“Female-donor mismatch” was labeled when a male reci-
pient received a kidney from a female donor. Patients were
grouped as female donor to male recipient or all other
combinations (female to female, male to male, or male to
female).
The difference between donor and recipient age (recipi-
ent age subtracted from donor age) was divided into four
groups, each representing approximately 25% of the
patients according to quartiles (1stQ: <15 years; 2ndQ:
≥15 and ≤4 years; 3rdQ: >4 and ≤+6 years; 4thQ:
>+6 years). Donors over the age of 60 or donors over the
age of 50 with two of the following were classified as ECD:
history of high blood pressure, serum creatinine ≥1.5 mg/
dl, or death resulting from a stroke.
Graft loss was defined as the absence of kidney function
occurring any time after transplantation due to either
patient death with a functioning allograft (“patient death”)
or irreversible graft injury requiring chronic dialysis and/or
retransplantation (“graft failure”).
Statistical analyses
Descriptives of baseline characteristics that were identified
by univariate survival analysis (unadjusted) or traditionally
considered as potential confounders for graft loss were cal-
culated, and the results are shown across DGF-AR groups
(Table 1). The following potential confounders were exam-
ined in unadjusted and adjusted multivariable models: (i)
recipient factors (age, cause of ESRD, PRA-peak, time on
dialysis prior to transplant, HCV infection status); (ii)
donor factors (ECD versus standard deceased-donor); and
(iii) transplant factors (number of HLA mismatches,
donor-age difference, “female-donor mismatch”, and
Transplant Era). Continuous variables are expressed as the
mean and standard deviation (SD), and categorical vari-
ables are expressed as proportions.
Survival analysis was performed for analyzing graft and
patient survival. To analyze graft survival, the event of
interest was graft failure and the competing risk event was
patient death with graft function. To analyze patient sur-
vival, the event of interest was patient death with graft
function and the competing end point was graft failure.
Patients without any of these outcomes were censored at
the date of their last recorded visit or at the end of the study
period (December 2013).
First, estimates of CIF taking competing risks into
account were calculated and compared with the (1-km)
estimates. Second, regression models taking competing
risks into account were carried out to analyze the effect of
covariates in the graft and in the patient survival. This
analysis was performed considering two types of hazard:
cause-specific hazard and subdistribution hazard. Propor-
tional cause-specific hazard regression models were per-
formed using the standard Cox cause-specific hazard
regression model, censoring all patients without the event
of interest. An alternative model proposed by Fine and
Gray [26] was the approach used in the current study to
model the subdistribution hazard.
An exploratory analysis was performed to examine the
unadjusted effect of the traditional potential confounders
by fitting univariable models. The cause-specific hazard
ratio (csHR) and the subdistribution hazard ratio (sHR)
for graft loss either due to declining function or to
patient death according to the primary exposure of inter-
est (DGF-AR) were estimated in a multivariable analysis
adjusting for the influence of these potential confound-
ers. The group of categorical variables with lower pro-
portion of the end point (graft failure or patient death)
was considered as the reference class. Therefore, the 1st
and the 4th quartiles of donor-age difference were con-
sidered the reference classes in graft and patient survival,
respectively.
As the main objective of this study was to assess the
prognostic value of a specific variable of interest
(DGF-AR), we opted to study the impact of DGF-AR in
graft and patient survival after adjusting for other risk fac-
tors traditionally considered as potential confounders in
the model, even those that were nonsignificant. The impact
of DGF-AR on graft and patient survival was similar when
including in the model only the statistical significant vari-
ables (supplemental data).
About 37.4% (n = 479) of patients had at least one vari-
able missing. The main variable of interest DGF-AR and
the survival outcome (patient death and graft failure) pre-
sented no missing values. Missing data were considered to
be missing completely at random. Therefore, missing data
were dealt by carrying complete case analyses, in which
patients were excluded in multivariable analyses if the
required variables were missing.
Statistical analyses were performed using SPSS version
22.0 (IBM SPSS Statistics, IBM Corporation, Chicago,
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Table 1. Patient demographic and clinical characteristics by DGF-AR occurrence (n = 1281).
Characteristic No DGF nor AR (n = 721) DGF only (n = 274) AR only (n = 175) DGF + AR (n = 111)
Recipient
Age (yr), mean (SD) 43.8 (12.3) 46.0 (12.3) 36.8 (12.2) 39.8 (12.4)
Gender
Male 427 (54.9) 175 (22.5) 111 (14.3) 65 (8.4)
Female 294 (58.4) 99 (19.7) 64 (12.7) 46 (9.1)
Cause of ESRD (n, %)
Glomerulonephritis 274 (57.7) 96 (20.2) 69 (14.5) 36 (7.6)
Diabetes 40 (56.3) 18 (25.4) 5 (7.0) 8 (11.3)
Other 407 (55.4) 160 (21.8) 101 (13.7) 67 (9.1)
Peak PRA (n, %)
<10 533 (60.4) 1784 (20.8) 99 (11.2) 67 (7.6)
≥10 92 (45.8) 50 (24.9) 34 (16.9) 25 (12.4)
Unknown/missing 96 (48.7) 40 (20.3) 42 (21.3) 19 (9.6)
Time on dialysis (mo)
Mean (SD) 3.9 (3.6) 4.2 (3.4) 3.3 (3.1) 4.0 (3.5)
≥ 5 years (n, %) 198 (57.6) 78 (22.7) 35 (10.2) 33 (9.6)
Unknown/missing 31 (57.4) 17 (31.5) 4 (7.4) 2 (3.7)
HCV infection (n, %)
HCV-negative 608 (56.6) 229 (21.3) 151 (14.1) 86 (8.0)
HCV-positive 58 (48.3) 36 (30.0) 12 (10.0) 14 (11.7)
Unknown/missing 55 (63.2) 9 (10.3) 12 (13.8) 11 (12.6)
Donor
Age (yr), mean (SD) 37.7 (14.5) 39.9 (14.9) 36.0 (12.9) 37.3 (12.4)
ECD (n, %) 84 (49.4) 55 (32.4) 18 (10.6) 13 (7.6)
Unknown/missing 9 (69.2) 2 (15.4) 1 (7.7) 1 (7.7)
Donor-Recipient
Cold ischemia time (h)
Mean (SD) 22.2 (8.6) 23.9 (4.9) 22.8 (4.1) 24.0 (4.6)
Unknown/missing (n, %) 389 (65.2) 107 (17.9) 63 (10.6) 38 (6.4)
HLA mismatches
A 1.23 (0.67) 1.17 (0.70) 1.22 (0.63) 1.22 (0.61)
Unknown/missing 42 (64.6) 11 (16.9) 11 (16.9) 1 (1.5)
B 1.21 (0.68) 1.24 (0.67) 1.35 (0.67) 1.29 (0.71)
Unknown/missing 39 (61.9) 12 (19.0) 11 (17.4) 1 (1.6)
DR 0.68 (0.69) 0.61 (0.66) 0.74 (0.73) 0.63 (0.64)
Unknown/missing 35 (54.7) 13 (20.3) 12 (18.8) 4 (6.3)
Female-donor mismatch
Yes 82 (33.2) 50 (20.2) 21 (8.5) 94 (38.1)
No 523 (61.4) 186 (21.8) 133 (15.6) 10 (1.2)
Unknown/missing 116 (63.7) 38 (20.9) 21 (11.5) 7 (3.8)
Donor-recipient age difference (n, %)
≤ 15 yr than recipient 183 (61.4) 67 (22.5) 31 (10.4) 17 (5.7)
15.1 to 4 yr than recipient 162 (54.4) 69 (23.2) 39 (13.1) 28 (9.4)
4.1 to +6 yr than recipient 157 (52.7) 59 (19.8) 49 (16.4) 33 (11.1)
> + 6 yr than recipient 150 (52.1) 57 (19.8) 50 (17.4) 31 (10.8)
Unknown/missing (n, %) 69 (77.5) 12 (13.5) 6 (6.7) 2 (2.2)
Transplantation Era
1983–1990 46 (29.5) 31 (19.9) 39 (25.0) 40 (25.6)
1990–1995 152 (49.4) 70 (22.7) 58 (18.8) 28 (9.1)
1996–2000 150 (55.8) 62 (23.0) 41 (15.2) 16 (5.9)
2001–2012 371 (69.2) 104 (19.4) 37 (6.9) 24 (4.5)
Percentages are calculated within DGF-AR status. ERSD, end-stage renal disease; ECD, expanded-criteria donors; HCV, Hepatitis C virus; SD, standard
deviation; yr, year. No missing values for the variables: recipient age and gender, cause of ERSD, and transplantation era.
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IL, USA) and R software using the packages coxph and
cmprsk. A significance level of 0.05 was considered.
Results
Sample
The final sample included 1281 primary adult kidney recipi-
ents transplanted between 1983 and 2012. About 60.7% were
male, and the overall mean age was 43.0 years (SD = 12.6).
Median follow-up was 9.8 years (range 1.0–30.2 years). A
total of 424 (33.1%) grafts were lost during the study period,
either as a result of loss of function (n = 258, 60.8%) or
patient death (n = 166, 39.2%). The main causes of patient
death with graft function were cardiovascular disease
(n = 63, 38.0%), followed by malignancies (n = 35, 21.1%)
and infection (n = 26, 15.7%).
Cumulative incidence function
Figure 1 summarizes the cumulative incidence estimates
for the two possible outcomes taking competing risks into
accounts (the survival plots were halted at 25 years because
the proportion of patients free of an event, but still in fol-
low-up, becomes small). The probabilities of experiencing
graft failure by 5, 10, and 20 years after KTx were 0.06,
0.14, and 0.32, respectively. The probabilities of death with
graft function were 0.03, 0.09, and 0.19, respectively.
Cumulative incidence estimates versus the complement of
Kaplan–Meier estimates
Figure 2 presents the curves for the CIF of the occurrence
of the event of interest obtained using two different meth-
ods: taking competing risks into account and the 1-KM.
The appropriate competing risks approach to estimate
CIF results in a lower estimate of cumulative incidence.
The magnitude of the difference in the incidence of graft
Number at risk 
Graft failure 1281 1000 722 506 301 191 
Patient death 1281 1029 773 575 393 284

















Death with graft function
Figure 1 Cumulative incidence curves for all possible outcomes taking
































0 5 10 15 20 25
Years





Figure 2 The complement of the Kaplan–Meier estimate and the cumulative incidence estimate for graft failure and death with graft function. CR,
competing risks; 1-KM, Complement of Kaplan–Meier estimate.
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failure and patient death, as calculated using the two meth-
ods, increases with the period of follow-up, mainly after the
tenth year. In other words, the actual probabilities of graft
failure and patient death are overestimated using the
Kaplan–Meier method. Furthermore, the longer the dura-
tion of follow-up is the larger the difference between the
estimates by these two methods.
Delayed graft function and acute rejection
The overall incidence of DGF was 30.1% (385 grafts)
and was not associated with AR in 274 grafts (21.4%)
and was associated with AR in 111 (8.7%). The overall
occurrence of DGF declined over decades from 45.5% in
Era 1 to 31.8% in Era 2, 29.0% in Era 3, and 23.9% in
Era 4. The overall incidence of AR similarly decreased
from 50.6% in Era 1 to 27.9% in Era 2, 21.2% in Era 3,
11.4% in Era 4. The characteristics of the recipients
according to DGF-AR status are summarized in Table 1.
The Fig. 3 displays the cumulative incidence curves for
graft failure and death with graft function according to
DGF-AR status. Differences were found between DGF-
AR status with regard to the graft failure: all three cate-
gories of the variable DGF-AR (DGF only, AR only, and
both DGF and AR) had a higher probability of graft
failure than the non-DGF/non-AR category. Concerning
patient survival, the differences between DGF-AR groups
were not so pronounced.
The impact of DGF on graft and patient survival by Cox
and Fine and Gray regression models
Tables 2 and 3 give a summary of the unadjusted and
adjusted effects of covariates for graft failure and patient
death with graft function based on the two types of models:
the cause-specific hazard model (standard Cox propor-
tional hazards regression) and the subdistribution hazard
model (Fine and Gray model).
Graft failure








Death with graft function
Number at risk at: (years) 0 5 10 15 20 25 
Graft failure 
No DGF nor AR 721 555 392 268 148 88 
DGF 274 221 166 115 78 55 
AR 175 144 101 76 39 25 
DGF + AR 111 80 63 47 36 23 
Patient Death 
No DGF nor AR 721 552 388 267 157 96 
DGF 274 228 173 123 88 65 
AR 175 159 135 120 89 74 
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Figure 3 Cumulative incidence curves for graft failure and death with graft function according to DGF-AR status. DGF, Delayed graft function; AR,
acute rejection.
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Graft survival
The variables identified as significant predictors of graft
failure in unadjusted cause-specific hazard models, and
unadjusted Fine and Gray models were similar (Tables 2
and 3). In both statistical approaches, all three categories of
the variable DGF-AR (DGF only, AR only, and both DGF
and AR) had a deleterious effect on graft survival compared
to the neither DGF nor AR category. The other covariates
associated with graft failure were the Transplant Eras (Eras
1 and 2 vs. 4), grafts from ECD, donor-recipient age differ-
ence (2nd, 3rd, and 4th quartiles vs. 1st quartile), cause of
ERSD (diabetes vs. other), positive HCV status (nearly
reaching the significance level in Fine and Gray model) and
recipient age.
In multivariable models (Tables 2 and 3, cause-specific
and subdistribution hazard models, respectively), DGF with
or without AR as well as AR only remained consistently
associated with graft failure. Furthermore, recipients whose
cause of ERSD was diabetes (nearly reaching the signifi-
cance level in the cause-specific hazard model), transplanta-
tion in Eras 1 and 2, kidneys from ECD or from donors
with an age difference of more than 6 years, were also asso-
ciated with poor graft survival. In both models, when the
donor-recipient age difference was added, the recipient’s
age became nonsignificant.
Patient survival
In relation to patient death with graft function, in the
unadjusted cause-specific hazard models and unadjusted
Fine and Gray models, the predictors of patient survival
were slightly different among models (Tables 2 and 3). In
the unadjusted cause-specific hazard models, the variables
DGF (isolated or associated to AR), Transplant Era, ECD,
donor-recipient age difference, cause of ERSD, pretrans-
plant time on dialysis, PRA-peak, HCV status, and recipi-
ent age were significantly associated with patient death
(Table 3). In the unadjusted Fine and Gray model, how-
ever, the variables identified as predictors of patient
Table 2. Cox proportional hazard regression (cause-specific hazard model) for all possible events.
Unadjusted models Adjusted model (n = 802)
csHR 95% CI P value csHR 95% CI P value
Graft Failure (censored for patient death) DGF-AR (reference: non-DGF and non-AR)
Only DGF 1.79 1.28–2.48 0.001 2.00 1.30–3.07 0.002
Only AR 2.99 2.17–4.10 <0.001 2.81 1.81–4.38 <0.001
DGF + AR 3.37 2.35–4.84 <0.001 2.60 1.58–4.27 <0.001
Transplant Era (reference: Era 4 > 2000)
Era 1 (<1990) 2.58 1.65–4.03 <0.001 3.21 1.47–7.04 0.004
Era 2 (1990–1995) 2.03 0.34–3.09 0.001 3.64 1.73–7.62 0.001
Era 3 (1996–2000) 0.92 0.57–1.49 0.74 1.66 0.78–3.55 0.19
ECD (yes vs. no) 2.41 1.73–3.34 <0.001 2.49 1.35–4.60 0.003
Donor-recipient age difference (reference: 1st Q: < - 15 yr)
2nd Q (≥15 and ≤ 4 yr) 1.76 1.16–2.69 0.009 1.60 0.89–2.88 0.12
3rd Q (> - 4 and ≤ +6 yr) 2.35 1.56–3.53 <0.001 1.73 0.94–3.21 0.081
4th Q (> + 6 yr) 3.91 2.66–5.77 <0.001 2.62 1.32–5.20 0.006
Cause of ESRD (reference: others)
Diabetic nephropathy 1.71 1.01–2.89 0.046 1.21 0.47–3.12 0.069
Glomerulonephritis 1.12 0.87–1.45 0.38 0.75 0.75–1.47 0.77
Time on dialysis (>5 vs. <5 yr) 1.24 0.93–1.65 0.14 1.42 0.97–2.06 0.13
Peak PRA (>10 vs. <10) 1.26 0.92–1.73 0.15 0.93 0.63–1.35 0.69
HCV infection (positive vs. negative) 1.43 1.02–2.00 0.039 1.12 0.73–1.70 0.61
Female-donor mismatch (yes vs. no) 0.98 0.68–1.44 0.98 0.84 0.50–1.41 0.51
HLA MM A (reference: 0)
1 vs. 0 1.18 0.80–1.74 0.19 1.19 0.71–1.97 0.51
2 vs. 0 1.24 0.82–1.89 0.17 1.21 0.70–2.11 0.50
HLA MM B (reference: 0)
1 vs. 0 1.04 0.71–1.52 0.77 1.16 0.71–1.92 0.55
2 vs. 0 1.12 0.75–1.67 0.57 1.46 0.87–2.47 0.16
HLA MM DR (reference: 0)
1 vs. 0 1.02 0.79–1.33 0.75 1.00 0.72–1.41 0.97
2 vs. 0 0.65 0.36–1.15 0.11 0.74 0.34–1.59 0.44
Recipient age (1-yr increase) 0.97 0.96–0.98 <0.001 0.99 0.97–1.01 0.27
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survival were as follows: DGF (DGF only vs. non-DGF/
non-AR), Transplant Eras (Eras 1 and 2 vs. Era 4), donor-
recipient age difference (1st, 2nd, and 3rd quartiles vs. 4th
quartile), cause of ERSD (glomerulonephritis, associated
with decreased HR), time on dialysis, PRA-peak, and reci-
pient age.
Considering the multivariable regression models, the
cause-specific hazard model showed that DGF only, Trans-
plant Eras 1 and 2, diabetes as the cause of ESRD,
pretransplant time on dialysis ≥5 years, positive HCV
status and increasing recipient age had a deleterious effect
on patient survival (Table 3). In the Fine and Gray
adjusted model, only recipient age and Transplant Eras 1
and 2 were significantly associated with patient death
(Table 4). In both models, Transplant Era (Era 2 vs. Era
4) emerged as significant when adjusted for any of the
other variables included.
Unlike the adjusted cause-specific hazard model, the
adjusted Fine and Gray model found that DGF was not
significantly associated with patient death (csHR = 1.57,
95% CI = 1.05–2.35, P = 0.029 vs. sHR = 1.22, 95%
CI = 0.85–1.76, P = 0.28). These differences are related to
the different composition of the risk sets (in contrast to the
cause-specific model where the DGF recipients who lost
their graft were censored and removed from the risk set, in
the subdistribution model, these same patients are main-
tained in the risk set) and to the increased risk of graft fail-
ure found for the recipients with DGF (these recipients had
a 57% higher hazard risk of graft failure compared to non-
DGF/non-AR: sHR = 1.57 95% CI = 1.12–2.21,
P = 0.009).
Discussion
In this study, application of a regression model for subdis-
tribution hazard showed that DGF, alone and independent
of AR, has a significant detrimental effect on long-term
graft survival but not on patient survival. Despite the
Table 2. continued
Unadjusted models Adjusted model (n = 802)
csHR 95% CI P value csHR 95% CI P value
Patient Death (censored for graft failure) DGF-AR (reference: non-DGF and non-AR)
Only DGF 1.95 1.41–2.68 <0.001 1.57 1.05–2.35 0.029
Only AR 1.29 0.85–1.95 0.23 1.19 0.69–2.03 0.54
DGF + AR 2.36 1.57–3.54 <0.001 1.34 0.76–2.34 0.31
Transplant Era (reference: Era 4 > 2000)
Era 1 (< 1990) 2.63 1.69–4.08 <0.001 5.29 2.59–10.8 <0.001
Era 2 (1990–1995) 1.39 0.90–2.14 0.139 3.11 1.58–6.12 0.001
Era 3 (1996–2000) 0.73 0.45–1.20 0.214 1.12 0.56–2.23 0.76
ECD (yes vs. no) 1.58 1.05–2.37 0.027 0.82 0.39–1.70 0.59
Donor-recipient age difference (reference: 4th Q: > +6 yr)
1st Q (<15 yr) 1.54 1.04–2.28 0.03 0.55 0.28–1.11 0.55
2rd Q (≥15 and ≤ 4 yr) 1.10 0.72–1.68 0.65 0.70 0.38–1.31 0.70
3rd Q (> - 4 and ≤ +6 yr) 1.14 0.74–1.74 0.56 0.79 0.45–1.38 0.79
Cause of ESRD (reference: others)
Diabetic nephropathy 2.56 1.60–4.11 <0.001 4.07 2.03–8.18 <0.001
Glomerulonephritis 0.76 0.57–1.02 0.071 0.90 0.62–1.32 0.60
Time on dialysis (>5 vs. <5 yr) 1.71 1.28–2.29 <0.001 1.49 1.01–2.20 0.048
Peak PRA (>10 vs. <10) 1.46 1.06–2.01 0.021 1.29 0.89–1.86 0.18
HCV infection (positive vs. negative) 1.87 1.32–2.65 <0.001 1.56 1.00–2.41 0.048
Female-donor mismatch (yes vs. no) 1.06 0.72–1.58 0.76 1.27 0.80–2.04 0.31
HLA MM A (reference: 0)
1 vs. 0 0.75 0.51–1.10 0.15 0.86 0.53–1.39 0.53
2 vs. 0 0.83 0.55–1.25 0.32 1.17 0.69–1.98 0.56
HLA MM B (reference: 0)
1 vs. 0 1.27 0.82–1.98 0.47 1.19 0.69–2.03 0.54
2 vs. 0 1.37 0.86–2.17 0.58 1.40 0.81–2.41 0.23
HLA MM DR (reference: 0)
1 vs. 0 1.08 0.81–1.45 0.67 0.95 0.66–1.37 0.78
2 vs. 0 1.22 0.74–2.00 0.07 1.18 0.65–2.14 0.59
Recipient age (1-yr increase) 1.04 1.02–1.05 <0.001 1.05 1.03–1.08 <0.001
csHR, cause-specific hazard ratio; ERSD, end-stage renal disease; ECD, expanded-criteria donors; HCV, Hepatitis C virus; PRA, panel reactive antibody;
HLA MM, HLA mismatches; yr, year; Q, quartile. The bold printed covariables indicate statistical significance in the multivariable model.
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common use in clinical cancer research, the estimation of
CIF and the application of competing risks models in
nephrology is relatively recent [23, 29–38]. To the best of
our knowledge, this is the first study that used a competing
risks approach to address the impact of DGF on graft and
patient survival.
Some previous studies have suggested that DGF without
AR may have no impact on long-term graft survival [5–8].
Consistent with other reports [9–11], using both of the sta-
tistical approaches, our findings support that DGF per se is
an independent predictor of graft failure. In fact, after
adjusting for most of the factors traditionally associated
with graft failure, early kidney dysfunction has a clear
adverse effect on long-term graft survival meaning that the
presence or absence of DGF will give an indication of the
life expectancy of the kidney graft.
In addition to the DGF-AR status, the other factors inde-
pendently associated with graft failure were, as expected,
Transplant Eras 1 and 2, grafts from ECD donors, diabetes
as a cause of ERSD and increasing donor-recipient age
difference. Compared to donors who were more than
15 years younger than their recipients, all other categories
showed a trend toward an increased risk of graft failure,
including the category of donors who were 4–15 years
younger than the recipient, with a near significant hazard
of failure by the subdistribution approach. This finding was
somewhat unexpected. The donor-recipient age difference
was studied mostly in recipients from living donors. Grafts
donated by live donors who were significantly older than
recipients had similar graft and patient survival compared
to recipients who received organs of a similar vintage [29,
39]. Shin et al. [40] evaluated whether the effect of donor
age was different according to recipient age (≤21, 20 to
1, 0–20, and ≥ 21 years) in kidneys from deceased
donors. The authors confirmed that a negative donor-reci-
pient age difference (recipients receiving kidneys from a
donor younger than the recipient) was associated with
greater death-censored graft survival. Our findings are in
the line with this study. However, we did not expect that
the narrow difference of donor-recipient age that we
Table 3. Fine and Gray model (hazard of the subdistribution model) for all possible events.
Unadjusted models Adjusted model (n = 802)
sHR 95% CI P value sHR 95% CI P value
Graft Failure DGF-AR (reference: non-DGF and non-AR)
Only DGF 1.69 1.21–2.35 0.002 1.57 1.12–2.21 0.009
Only AR 3.09 2.24–4.27 <0.001 2.57 1.85–3.56 <0.001
DGF + AR 3.26 2.28–4.67 <0.001 2.26 1.52–3.37 <0.001
Transplant Era (reference: Era 4 > 2000)
Era 1 (< 1990) 2.69 1.74–4.18 <0.001 1.87 1.11–3.14 0.019
Era 2 (1990–1995) 2.23 1.49–3.33 0.001 1.93 1.23–3.03 0.004
Era 3 (1996–2000) 1.02 0.64–1.65 0.93 0.96 0.58–1.60 0.88
ECD (yes vs. no) 2.10 1.51–2.92 <0.001 1.73 1.09–2.74 0.019
Donor-recipient age difference (reference: 1st Q: < 15 yr)
2nd Q (≥15 and ≤ 4 yr) 1.82 1.20–2.76 0.005 1.56 0.97–2.50 0.066
3rd Q (>4 and ≤ +6 yr) 2.36 1.60–3.50 <0.001 1.65 1.01–2.70 0.049
4th Q (> + 6 yr) 4.06 2.79–5.90 <0.001 2.52 1.44–4.41 0.001
Cause of ESRD (reference: others)
Diabetic nephropathy 1.71 1.01–2.89 0.046 2.23 1.27–3.92 0.005
Glomerulonephritis 1.12 0.87–1.45 0.38 1.08 0.83–1.41 0.57
Time on dialysis (≥5 vs. <5 yr) 1.13 0.86–1.49 0.39 1.27 0.93–1.73 0.13
Peak PRA (>10 vs. <10) 1.16 0.86–1.56 0.34 1.00 0.70–1.42 0.99
HCV infection (positive vs. negative) 1.38 0.99–1.91 0.058 1.27 0.88–1.84 0.21
Female-donor mismatch (yes vs. no) 0.96 0.66–1.42 0.85 1.02 0.69–1.49 0.94
HLA MM A (reference: 0)
1 vs. 0 1.29 0.89–1.87 0.19 1.00 0.69–1.45 1.00
2 vs. 0 1.33 0.89–1.99 0.17 1.12 0.75–1.68 0.57
HLA MM B (reference: 0)
1 vs. 0 1.05 0.74–1.51 0.77 1.08 0.73–1.59 0.71
2 vs. 0 1.12 0.76–1.63 0.57 1.31 0.88–1.96 0.19
HLA MM DR (reference: 0)
1 vs. 0 1.04 0.81–1.35 0.75 1.08 0.82–1.43 0.57
2 vs. 0 0.64 0.37–1.11 0.11 0.80 0.47–1.37 0.42
Recipient age (1-yr increase) 0.97 0.96–0.98 <0.001 0.99 0.97–1.01 0.20
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Table 3. continued
Unadjusted models Adjusted model (n = 802)
sHR 95% CI P value sHR 95% CI P value
Patient
Death
DGF-AR (reference: non-DGF and non-AR)
Only DGF 1.53 1.08–2.19 0.018 1.22 0.85–1.76 0.28
Only AR 0.80 0.49–1.30 0.370 0.84 0.50–1.41 0.51
DGF + AR 1.29 0.78–2.15 0.320 1.10 0.63–1.93 0.74
Transplant Era (reference: Era 4 > 2000)
Era 1 (< 1990) 1.80 1.09–2.95 0.021 3.74 2.00–7.02 <0.001
Era 2 (1990–1995) 1.29 0.81–2.04 0.280 2.13 1.25–3.62 0.005
Era 3 (1996–2000) 0.75 0.44–1.27 0.280 1.03 0.59–1.78 0.93
ECD (yes vs. no) 1.14 0.70–1.85 0.60 0.88 0.49–1.71 0.70
Donor-recipient age difference (reference: 4th Q: > +6 yr)
1st Q (<15 yr) 3.07 1.90–4.95 <0.001 1.20 0.65–2.20 0.57
2rd Q (≥15 and ≤ 4 yr) 1.71 1.01–2.88 0.044 1.19 0.68–2.08 0.56
3rd Q (>4 and ≤ +6 yr) 1.82 1.07–3.10 0.027 1.54 0.90–2.65 0.12
Cause of ESRD (reference: others)
Diabetic nephropathy 1.41 0.75–2.64 0.28 1.84 0.97–3.49 0.064
Glomerulonephritis 0.62 0.44–0.88 0.007 0.76 0.54–1.07 0.12
Time on dialysis (≥ 5 vs. <5 yr) 1.62 1.17–2.24 0.004 1.24 0.86–1.78 0.25
Peak PRA (>10 vs. <10) 1.61 1.14–2.27 0.007 1.29 0.89–1.86 0.18
HCV infection (positive vs. negative) 1.39 0.92–2.11 0.12 0.99 0.62–1.57 0.95
Female-donor mismatch (yes vs. no) 1.21 0.80–1.85 0.37 1.37 0.91–2.07 0.13
HLA MM A (reference: 0)
1 vs. 0 0.74 0.49–1.11 0.15 0.79 0.52–1.19 0.26
2 vs. 0 0.80 0.51–1.25 0.32 0.84 0.53–1.35 0.47
HLA MM B (reference: 0)
1 vs. 0 1.18 0.75–1.86 0.47 1.09 0.70–1.71 0.70
2 vs. 0 1.14 0.71–1.83 0.58 1.00 0.62–1.62 0.99
HLA MM DR (reference: 0)
1 vs. 0 1.08 0.77–1.5 0.67 1.00 0.72–1.41 0.98
2 vs. 0 1.62 0.97–2.71 0.07 1.43 0.85–2.42 0.18
Recipient age (1-yr increase) 1.05 1.04–1.06 <0.001 1.06 1.04–1.08 <0.001
sHR, subdistribution hazard ratio; ERSD, end-stage renal disease; ECD, expanded-criteria donors; HCV, Hepatitis C virus; PRA, panel reactive antibody;
HLA MM, HLA mismatches; yr, year; Q, quartile. The bold printed covariables indicate statistical significance in the multivariable model.
considered would have a significant effect. We believe that
this result emphasizes the advantage of young donors for
long-term graft survival.
No clear effect of DGF on patient outcome has been
reported. Some studies highlight the association between
DGF and mortality, [9, 14, 17] whereas others [6, 8, 13]
have not found a significant effect. None of these studies
accounted for competing risks.
In our study, we confirmed this association using a stan-
dard Cox proportional hazards regression, but not when
modeling cumulative incidence of the failure types (Fine
and Gray models). Both approaches are valid, and the choice
of the appropriate approach depends on the research ques-
tion. To better understand and discuss this finding, we first
give an overview of competing risks in the context of KTx.
Survival analysis involves the statistical analysis of the
time to the occurrence of an event. However, in biomedical
research, the need to address multiple potential outcomes
is nearly ubiquitous. Competing risks are used to model a
situation in which subjects under investigation are exposed
to several causes of failure, such as graft failure or death
with graft function. These two events are mutually exclu-
sive, and only the first event that occurs is observed. Thus,
the analysis and interpretation of competing risk data differ
from survival analysis with only a single cause of failure. As
such appropriate methods must be applied.
The estimated cumulative incidence of an event of inter-
est using the 1-KM estimate is, in general, higher than esti-
mates obtained when accounting for competing risks [19,
41, 42]. This is because when an individual experiences a
competing risk event, this individual is treated as censored
and is eliminated from the risk set. Censored patients are
considered to have the same probability of experiencing the
event as patients who remain under follow-up [41]. How-
ever, a subject who is censored due to failure from a com-
peting risk (e.g., patient death) will clearly not experience
the event of interest (allograft loss functioning). Because
subjects who will never fail (by the failure of interest) are
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treated as if they could fail (they are censored), the 1-km
estimator overestimates the probability of failure and
underestimates the corresponding survival probability [19,
42]. We confirmed this finding, especially after the 10th
year of follow-up when the probability of graft failure and
patient death increases.
In the competing risk context, there are different
approaches to quantifying the effect of covariates in the
presence of competing events [26, 43]. In the current study,
the influence of DGF was evaluated using the cause-specific
Cox proportional hazards regression model (modeling the
cause-specific hazard) and the Fine and Gray regression
model (modeling the subdistribution hazards). We found
that the effect of this covariate differed between these two
approaches. Both results are valid, but their interpretation
is different and depends on the purpose of the study
(etiology vs. prediction) [23, 42, 44, 45].
If the primary interest in the etiological question of how
the covariates affect the event of interest, the cause-specific
hazards model would be most appropriate, because they
directly model the covariate effect on event rates among
subjects at risk [28]. Using this approach in the current
study, DGF significantly increases the risk of mortality
(csHR = 1.57, P = 0.029). This hazard can be interpreted
among those recipients who did not experience the event of
interest (patient death), that is, those recipients who were
censored because they were alive or had already been trans-
ferred for dialysis due to graft failure (competing event),
but they were alive when they were censored for graft fail-
ure. Considering our example, the csHR of 1.57 means that
a DGF recipient has a hazard of dying that is 1.57 higher
than non-DGF recipients, when considered among recipi-
ents who were alive and who did not experience graft fail-
ure at that time.
For the purposes of prognosis and medical decision-
making, the primary interest is in the absolute risks of the
event of interest; therefore, the subdistribution hazards
model would be more relevant [46]. This competing risk
analysis allows splitting the contribution of a covariate of
each event type separately. For our example, the effect of
DGF did not reach conventional significance. Furthermore,
the estimated effect (sHR = 1.22, P = 0.28) was smaller
than the corresponding DGF effect obtained by standard
Cox analysis (csHR = 1.57). The major advantage of the
competing risks approach is that the effects of each risk fac-
tor can be estimated and formally compared across differ-
ent end points.
The conflicting findings of the impact of DGF on graft
and patient survival results not only from the ambiguity in
the definition of DGF but also from the statistical method-
ology used to study its effect. The impact of DGF on two
types of graft loss was assessed in this study using specific
methods designed for the competing risks analysis and was
compared with the results of the standard survival analysis
methods. Accounting for the Fine and Gray model, DGF
was not significantly associated with patient death. How-
ever, it has a significant adverse effect on the hazard of graft
failure, independent of AR. The results stress the impor-
tance of using appropriate statistical methods if competing
risks are present.
This article also presents an overview of competing risks
concepts in the context of KTx, including the bias in the
standard Kaplan–Meier estimator. Competing risks are
clearly important for medical research, and their negligence
has important clinical implications. The naive interpretation
of Kaplan–Meier estimates in the presence of competing
risks as estimates of actual risks leads to potential overesti-
mation of the actuals probabilities of graft failure and patient
death and overestimation and inappropriate risk stratifica-
tion in prognostic models. This is markedly important in a
field such as kidney transplantation, where changes in sur-
vival-influencing factors, such as immunosuppression prac-
tices, organ allocation policies, or surgical techniques, may
occur rapidly and where competing events are pervasive.
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